Skip to main content

Table 3 Analytical results

From: Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project

Variable (normal values)

At switch (n = 28)

12 months (n = 27)

24 months (n = 21)

Hemoglobin (11.5–16 g/dL)

13.9 ± 1.6

13.9 ± 1.8

13.5 ± 1.6

Hematocrit (36–51%)

41.5 ± 2.7

41.6 ± 2.9

40.5 ± 2.8

VCM (80.0–101.0 fl)

90.1 ± 6.0

91.5 ± 5.2

92.0 ± 4.1

WBC (4.5–11 × 109/L)

7.3 ± 3.5

6.2 ± 1.6

6.5 ± 2.3

Neutrophils (2.6–8.5 × 109/L)

3.9 ± 1.6

3.7 ± 1.0

3.7 ± 1.1

Platelets (150–350 × 109/L)

196.8 ± 74.0

201.0 ± 87.3

213.0 ± 121.2

Glycemia (73–110 mg/dL)

116.7 ± 58.9

113.1 ± 39.2

94.1 ± 12.0

Creatinine (0.66–1.09 mg/dL)

0.7 ± 0.1

0.8 ± 0.2

0.7 ± 0.1

Urate (2.7–5.9 mg/dL)

4.8 ± 1.5

5.0 ± 1.1

5.0 ± 1.1

Cholesterol (< 200 mg/dL)

177.4 ± 40.5

185.5 ± 41.9

186.0 ± 53.2

Triglycerides (< 200 mg/dL)

96.1 ± 48.4

104.8 ± 54.4

98.3 ± 54.4

HDL (> 40 mg/dL)

54.7 ± 22.0

58.0 ± 23.4

65.4 ± 28.6

LDL (< 130 mg/dL)

102.0 ± 31.1

99.5 ± 38.0

110.9 ± 40.4

AST (< 35 U/L)

26.6 ± 11.0

21.3 ± 4.3

20.8 ± 4.2

ALT (< 35 U/L)

22.6 ± 9.8

21.4 ± 8.6

20.7 ± 8.6

LDH (140–280 U/L)

210.4 ± 86.0

202.5 ± 89.0

218.4 ± 75.7

GGT (< 38 U/L)

23.5 ± 21.6

21.9 ± 13.5

26.4 ± 25.7

B12 vitamin (200–900 pg/mL)

406.9 ± 149.2

449.8 ± 185.8

359.1 ± 94.0

Folate (2.7–17.0 ng/mL)

9.2 ± 7.0

13.3 ± 16.1

5.4 ± 2.3

Iron (27–151 µg/dL)

91.6 ± 29.5

92.0 ± 42.5

78.3 ± 24.2

Ferritin (males: 30–300 ng/mL

females: 30–200 ng/mL)

M: 503.0 ± 470.9

F: 256.0 ± 223.0

M: 459.6 ± 415.7

F: 184.1 ± 188.3

M: 260.7 ± 117.2

F: 237.0 ± 291.5

  1. Hematological, and biochemical laboratory test mean ± standard deviation before the switch and after 12 and 24 months with eliglustat